Product Search for survivin: Novus Biologicals

NB500-201

Survivin Antibody - BSA Free

(22 Reviews)

(380 Publications)

0.1 ml

NB500-201

<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Survivin-Antibody-Knockdown-Validated-NB500-201-img0037.jpg

Survivin-Antibody-Immunohistochemistry-NB500-201-img0038.jpg

<b>Genetic Strategies Validation. </b>Survivin-Antibody-Knockdown-Validated-NB500-201-img0033.jpg

Immunocytochemistry/Immunofluorescence: Survivin Antibody [NB500-201] - Analysis using the HRP conjugate of [NB500-201]. Staining of Telophase with accumulation of survivin in the midbodies of two daughter cells. Survivin detection using [NB500-201].

Western Blot: Survivin Antibody [NB500-201] - Analysis of 30ug of HeLa whole cell lysate [NB800-PC1] using rabbit polyclonal [NB500-201] at 1ug/ml. Detection was performed using ECL method with 1 minute exposure. Band detected at higher molecular weight than the predicted MW (16 kDa).

Immunohistochemistry-Paraffin: Survivin Antibody [NB500-201] - Immunohistochemical staining of Survivin in human rectal cancer using [NB500-201] and DAB with hematoxylin counterstain.

Flow Cytometry: Survivin Antibody [NB500-201] - An intracellular stain was performed on HeLa cells with [NB500-201] and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550.

Western Blot: Survivin Antibody [NB500-201] - Analysis of Survivin in human hepatocytes from cancer patient (left) and HeLa cell lysate (right) using [NB500-201]. Image from verified customer review. Note: bands detected at higher molecular weight than predicted (16 kDa)

<b>Biological Strategies Validation. </b>Survivin-Antibody-Western-Blot-NB500-201-img0028.jpg

Immunocytochemistry/Immunofluorescence: Survivin Antibody [NB500-201] - Analysis of HeLa cells using Survivin Antibody ([NB500-201], 1:10). An Alexa Fluor 488-conjugated Goat to rabbit IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).

Immunohistochemistry-Paraffin: Survivin Antibody [NB500-201] - Analysis of Survivin in ovarian cancer tissue using [NB500-201]. Image from verified customer review.

Immunohistochemistry: Survivin Antibody [NB500-201] - HRP conjugated Survivin expression in BIRC5 transfected 293T cells using Survivin Antibody [NB500-201]. Image from verified customer review.

Immunohistochemistry: Survivin Antibody [NB500-201] - Immunohistochemical analysis using [NB500-201]. The top photo is a control stain and the bottom photo is anti-survivin staining of melanoma. Photo courtesy of Dr. Dario Altieri, Yale University.

Immunohistochemistry-Paraffin: Survivin Antibody [NB500-201] - Survivin shows lysates of human neuroblastoma cell line. Polyvinylidene fluoride (PVDF) membrane was probed with 1:200 dilution of 0.5 ug/mL of rabbit polyclonal [NB500-201], followed by 1:2000 dilution of goat anti-rabbit IgG.

Simple Western: Survivin Antibody [NB500-201] - Simple Western analysis using [NB500-201]. Lane view shows a specific band for Survivin in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Theoretical molecular weight: 16 kDa.

Radiation-resistant Caveolin-1 (CAV1)-silenced fibroblasts differentially express and secrete the apoptosis inhibiting protein TP53-regulated inhibitor of apoptosis 1 (TRIAP1).

Expression of survivin protein in cell lines after transfection with siRNA.Survivin protein expression in CHS cell lines was evaluated by western blotting at 48 h after transfection with scrambled and survivin siRNA.

<b>Biological Strategies Validation. </b>Western blotting analysis in MDA-MB-231 cells and SUM 149 cells.The cells were treated for 24 h with C. juttae essential oil (EO) (46 and 64 μg/ml, respectively). The data shown are the results of a representative experiment.

(A) Levels of suppression of Survivin and expression of p53 for 2 h, 4 h and 8 h for MBA-MD 231 cells. (B) Light microscopy images of the three cell types using nanoconstruct with the AS1411 aptamer. Cell population had been observed to reduce for the MBA-MD 231 cells and AGS while the non-tumorigenic cells MCF-10a did not exhibit any appreciable loss in cell number as well as cell morphology.

Detection of BCL2, Bcl-xL, XIAP and survivin protein content by western blotting 48 h after transfection with a total of 40 nM siRNA in EJ28 bladder cancer cells. Beta-actin was used for loading control.

$Western Blot: Survivin Antibody - BSA Free [NB500-201] - Deficiency in CCAR2 or Hsp60 reduces expression of survivin. SH-SY5Y cells were transfected with Universal (siU), CCAR2 (siC), or Hsp60 (siH) siRNA. Forty-eight hours later, expression of survivin protein was examined by western blotting. (A) Survivin expression was detected in whole cell lysates. The relative level of survivin protein is presented as the mean ± standard error of the mean (SEM) (n = 3). Asterisks (*) denote statistically significant differences (p < 0.05, one-way ANOVA). (B) Cytosolic & mitochondrial fractions were isolated to determine localization & expression of survivin. (C) Two different siRNAs specific for CCAR2 & Hsp60 were used to knock down their expressions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30609639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin & BIM expression in response to lapatinibWestern analysis of Survivin & BIM protein levels after 24 hour exposure to 0.1% DMSO (−) or 2 μM lapatinib (+) in lapatinib-resistant cells (A), cells overexpressing t-Darpp (B), or SK/HerR cells transiently transfected with siRNA targeted to GFP (siCtrl) or Darpp-32/t-Darpp (siDp) for 72 hours (C). alpha -Tubulin was used as a loading control. Protein expression was quantified using ImageJ software. Data was normalized to alpha -Tubulin levels & expressed as the fold change in protein level after lapatinib treatment, relative to the DMSO control, for each cell line. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.5311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Expression of stem cell & differentiation markers in RAD, NRAD & TOT cells from cSCC. (A) Cells were analyzed immediately after separation, & levels of markers were determined by Western blot analysis. beta -actin was used as loading control; (B) Bar graphs show the average densitometry values normalized to actin. *p < 0.05; **p < 0.01. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/10/19540), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Expression of survivin protein in cell lines after transfection with siRNA.Survivin protein expression in CHS cell lines was evaluated by western blotting at 48 h after transfection with scrambled & survivin siRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24260303), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin protein stability is increased in the presence of autophagy inhibitors in serum-free media, but not in serum-containing media. Western blots & protein quantitation graphs showing survivin protein levels over time after addition of CHX (100 μM) to media. One representative western blot out of three repeat experiments was shown for each treatment & condition. The prominent band shown is survivin while the smaller bands are nonspecific, as determined via control experiments utilizing a neutralizing peptide for the survivin antibody. *Indicates the time at which survivin protein is half of the amount at 0 hours (half-life), P < 0.02. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23431290), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - (A) Levels of suppression of Survivin & expression of p53 for 2 h, 4 h & 8 h for MBA-MD 231 cells. (B) Light microscopy images of the three cell types using nanoconstruct with the AS1411 aptamer. Cell population had been observed to reduce for the MBA-MD 231 cells & AGS while the non-tumorigenic cells MCF-10a did not exhibit any appreciable loss in cell number as well as cell morphology. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-00912-3), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: Survivin Antibody - BSA Free [NB500-201] - Deficiency in CCAR2 or Hsp60 reduces expression of survivin. SH-SY5Y cells were transfected with Universal (siU), CCAR2 (siC), or Hsp60 (siH) siRNA. Forty-eight hours later, expression of survivin protein was examined by western blotting. (A) Survivin expression was detected in whole cell lysates. The relative level of survivin protein is presented as the mean ± standard error of the mean (SEM) (n = 3). Asterisks (*) denote statistically significant differences (p < 0.05, one-way ANOVA). (B) Cytosolic & mitochondrial fractions were isolated to determine localization & expression of survivin. (C) Two different siRNAs specific for CCAR2 & Hsp60 were used to knock down their expressions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30609639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Immunohistochemistry: Survivin Antibody - BSA Free [NB500-201] - RAD & NRAD-derived tumor characterization. (A) Mitotic Index representing the number of cells undergoing mitosis over total cells were counted in RAD & NRAD-derived tumors **p < 0.01; (B) Survivin & Ki67 expression in RAD & NRAD-derived tumors by immunohistochemistry. Scale bar = 200 μm; (C) K10, E-FABP & involucrin expression in RAD & NRAD-derived tumors by immunohistochemistry. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/10/19540), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Gene-silencing of Bcl-2, Survivin & XIAP. Western blot showed efficient silencing in transfected MiaPaCa-2 (A) & AsPC-1 cells (B). 50,000 cells/well were single-transfected with carrier solution (lane 1) & siRNA against Luciferase (lane 2) as control. SGS, lowST & ST all effectively silenced the three target genes (lane 3-5). Efficient knock-down was also shown in the lowST group by RT-PCR in MiaPaCa-2 (C) & AsPC-1 cells (D). White bars show controls, grey bars signify transfected cells. All samples were normalized to beta -Actin as a house-keeping gene. SGS = Simultaneous gene silencing; lowST = Low dose siRNA transfection; ST = Standard dose siRNA transfection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/20646298), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: Survivin Antibody - BSA Free [NB500-201] - CCAR2 binds Hsp60 & survivin. Interaction between CCAR2 & survivin was examined in SH-SY5Y or HEK293 cells by co-immunoprecipitation with either an anti-CCAR2 or an anti-survivin antibody, followed by western blotting. (A) Interaction between CCAR2 & survivin in whole cell lysates from SH-SY5Y cells was examined. (B) Interaction between CCAR2, survivin, & Hsp60 in cytosolic & mitochondrial fractions isolated from HEK293 cells was examined. (C) SH-SY5Y cells were depleted of Hsp60 & the interaction between CCAR2 & survivin was examined. siU, universal siRNA; siH, Hsp60 siRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30609639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Radiation-resistant Caveolin-1 (CAV1)-silenced fibroblasts differentially express & secrete the apoptosis inhibiting protein TP53-regulated inhibitor of apoptosis 1 (TRIAP1). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30871022), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Western blotting analysis in MDA-MB-231 cells & SUM 149 cells.The cells were treated for 24 h with C. juttae essential oil (EO) (46 & 64 μg/ml, respectively). The data shown are the results of a representative experiment. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30921428), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Overexpression of Survivin predominantly protects anoikis. B. Caspase-3 activation in EGFP- & EGFP-Survivin-expressing cells after serum starvation under attached or detached culture conditions. Experimental protocol was illustrated in Figure S1. Transfection frequencies checked by using fluorescence microscopy & confirmed to be 80–90%. Cells kept in serum-free medium for 24–72 h, harvested, & lysed in Laemmli SDS-sample buffer for immunoblot analysis with anti-GFP, anti-Survivin, anti-activated caspase-3 antibody, anti-LC3B, & anti-alpha -tubulin.Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0055710), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Representative Western blots showing the IAP levels in EV derived from individual European American (EA) (N1-N5) & (N7-N9), *N6 & African American (AA) (N1-N9) patients with prostate cancer (PCa).Specific antibodies against Survivin, XIAP, cIAP-1, cIAP-2, & Lamp1 were used for the Western blotting analysis of total exosomal proteins. The blots from both patient groups were processed under identical conditions; Lamp 1 was used as loading control. (*N6, Hispanic.) (Both blots were done side by side in the same gel running & transferring apparatus, blocking, washing buffers, & antibody incubations were done in the same time, in the same incubating trays under the identical exposure to keep the consistencies.) Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0183122), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: Survivin Antibody - BSA Free [NB500-201] - CCAR2 binds Hsp60 & survivin. Interaction between CCAR2 & survivin was examined in SH-SY5Y or HEK293 cells by co-immunoprecipitation with either an anti-CCAR2 or an anti-survivin antibody, followed by western blotting. (A) Interaction between CCAR2 & survivin in whole cell lysates from SH-SY5Y cells was examined. (B) Interaction between CCAR2, survivin, & Hsp60 in cytosolic & mitochondrial fractions isolated from HEK293 cells was examined. (C) SH-SY5Y cells were depleted of Hsp60 & the interaction between CCAR2 & survivin was examined. siU, universal siRNA; siH, Hsp60 siRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30609639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Induction of cell death & suppression of survivin after L-OHP depends on p53(A) HCT116 wild typeand p53-/- cells were treated with 5 μM L-OHP or 10 μM CPT-11 for 24 hours. Protein levels of survivin, p53 & p21 were detected by Western blot analysis; vinculin serves as loading control. (B) Quantitative real-time PCR was performed to quantify BIRC5 mRNA levels in HCT116 wild type & p53-deficient cells after 24 hours treatment (** p < 0.01, n = 3). (C) Flow cytometric analysis of DNA content was done in HCT116 wild type & p53-/- cells after 24 hours treatment with L-OHP (n = 4). (D) SubG1-populations were detected in both cell lines after 48 hours treatment (*** p < 0.001, n = 4). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Detection of BCL2, Bcl-xL, XIAP & survivin protein content by western blotting 48 h after transfection with a total of 40 nM siRNA in EJ28 bladder cancer cells. Beta-actin was used for loading control. Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijo.2012.1549), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - PARP6 inhibits cell growth & colony formationA. A schematic illustration of the human PARP6 protein. PARP6 consists of 630 amino acid residues & has a PARP catalytic domain in C-terminal region. delta C-PARP6 lacks the PARP catalytic domain. B. Cell proliferation after FL-PARP6 & delta C-PARP6 overexpression in SW480 cells was measured by MTT assays. After transfection with the p-EGFP-empty, p-EGFP-FL-PARP6 or p-EGFP-delta C-PARP6 plasmids, transfectant cells (1500 cells / well) were replated in 96-well plates. The MTT assay was performed to test the cell viability at 24 h, 48 h & 72 h. Values indicate mean ± SD (n=6). C. Colony formation aof FL-PARP6 & delta C-PARP6 transfectant SW480 cells. Cells were plated in 6 cm dishes at a density of 500 cells per dish. After 2 weeks, number of colonies were counted. The data represent the means ± S.D. of three independent experiments **P < 0.01. D. Expression of cell cycle related proteins including Survivin, Cyclin B, Aurora-B, p21 & p27 in empty vector, FL-PARP6 & delta C-PARP6 transfectant SW480 cells was examined by Western blot analysis. beta -actin expression was used as a loading control. E. Expression of apoptosis related proteins including cleaved Caspase-3, Caspase-3, Bax, Bcl-2 & Bcl-XL in empty vector, FL-PARP6 & delta C-PARP6 transfectant SW480 cells was examined by Western blot analysis. beta -actin expression was used as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26934315), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Screening of epigenetic drugs for upregulation of miRNAs & downregulation of ZEB1Heat map showing the relative expression levels after drug treatment for 48 h in Panc1. Values measured by qRT–PCR were depicted with the software GENE-E. Only mocetinostat upregulated the miRNAs & downregulated ZEB1.Relative expression of indicated genes in Panc1 measured by qRT–PCR after treatment with different HDAC inhibitors. Note the downregulation of ZEB1 & upregulation of miR-203, miR-200, & E-cadherin by mocetinostat. n = 3, mean ± SEM; unpaired Student's t-test. For significance, see Supplementary Table S1.Immunoblot & immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression & induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.Chromatin immunoprecipitation analysis validated mocetinostat-induced (1 μM, 48 h) enrichment of the active histone marks H3ac, H4ac, H3K9ac, & H3K4me3 at ZEB1 target gene loci in Panc1. n = 3, mean ± SEM; unpaired Student's t-test.Mocetinostat treatment reduced expression of the anti-apoptotic miR-203 target survivin & sphere-forming capacity in Panc1 when pre-treated with mocetinostat for 48 h. n = 3, mean ± SEM; Mann–Whitney U-test.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25872941), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin is highly enriched in exosomes from PTX-treated cancer cells. (A) Western blot analysis using Survivin, flotillin, I kappa B alpha , & CD-63 antibodies was performed on lysates of MDAMB231 cells treated with either DMSO or PTX (lanes labeled WCL), as well as the exosomes (lanes labeled Exos) & MVs (lanes labeled MVs) generated by the cells. (B) The relative amounts of Survivin detected in exosomes generated by DMSO- & PTX-treated MDAMB231 cells. (C) Western blot analysis using Survivin & actin antibodies was performed on lysates of MDAMB231 cells treated with PTX for increasing lengths of time. (D) Immunofluorescence using a Survivin antibody was performed on MDAMB231 cells treated with either DMSO or PTX (top images). The cells were also stained with DAPI to label nuclei (bottom images). Arrows indicate areas where Survivin is detected as puncta in the cytosol of cells treated with PTX. Scale bar = 5 µm. (E) Western blot analysis was performed using a Survivin antibody on lysates of MDAMB231 cells, U87 glioblastoma cells, & SKBR3 cells that had been treated with DMSO or PTX (lanes labeled WCL), & on the exosomes these cells generated (lanes labeled Exos). (F) Western blot analysis was performed on lysates of exosomes from MDAMB231 cells that had been treated with the indicated chemotherapeutic agents & inhibitors. The experiments in B were performed a minimum of three separate times, with each experiment yielding similar results. Student t-tests were performed. *** p < 0.001. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/2072-6694/8/12/111), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - NPC-derived EBNA1 is compromised for interaction with SurvivinA. LC-MS analysis of proteins associated with FLAG-EBNA1 (F-EBNA1) from B95-8 or with the NPC DNA binding domain. Unique peptides & spectral counts are shown for USP7, BIRC5 (Survivin), & Tankyrase 1 (TNKS). B. Western blot analysis of FLAG IP from HeLa cells with stable expression of FLAG-vector, F-EBNA1 (B95-8) or F-EBNA1 (NPC) probed with antibody to USP7, Tankyrase 1, Survivin, or FLAG. C. Extracts from stable HeLa cells shown in panel B, were subject to IP with antibody to Survivin probed with antibody to FLAG or Survivin (top panel). Extracts from stable HeLa cells shown in panel B were subject to IP with antibody to Tankyrase 1 probed with antibody to FLAG or Tankyrase1 (lower panel). D. MutuI cell (top panels) or C666-1 cell (lower panels) extracts were subject to IP with antibody to EBNA1 or control IgG, & then assayed by Western blot with antibody to Survivin or EBNA1, as indicated. E. Same as in panel D, except IP with Suvivin or control IgG. F. In situ Proximity Ligation Assay (in situ PLA) is shown for interphase cells from either MUTU-I or C666-1 using mouse anti-EBNA1 & rabbit anti-Survivin. G. Quantification of in situ PLA for n > 100. ** p-value < .01 using student t-test. H. PFGE analysis of EBV episomes & linears at 7 days post-transduction with lentivirus shRNA for shControl or shSurvivin in MUTU I or RAJI cell lines. Human alpha satellite DNA is used for DNA loading control Western blot of Survivin & Actin are shown below for each cell at 7 days post-transduction. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28077791), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Anti-tumor effects & functional evidence of sCA-survivin-siRNA in HCT116 & HT29 solid tumor models.(A) For western blot analysis, HCT116 cells were seeded into 6-well plates & transfected with 100 pmol/well of either control or survivin siRNA by Lp (Lipofectamine 2000) or sCA. Actin blots served as loading controls. (B) For proliferation assays, cells were uniformly seeded into 96-well plates (1 × 104 cells/well), & 5 pmol/well siRNA was used. Cell viability was examined at 48 & 72 h by WST-8 assay. Data represent mean ± SEM. *P = 0.0294, **P = 0.0304 (n = 4, Wilcoxon rank test). (C) In vivo tumor growth. Each vehicle, carrying 15 μg of control siRNA or survivin siRNA, was administered by intravenous injection to mice with HCT116 tumors. Data represent the mean ± SEM (n = 10 tumors, Wilcoxon rank test). (D) Immunostaining of survivin in the tumor tissues on day 19. Scale bar, 50 μm. (E) In vivo live imaging of sCA-siRNA (6-FAM labeled) in HT29 tumor by multiphoton microscopy at 90 min. (F) Fluorescent detection of naked-siRNA (6-FAM labeled) or sCA-siRNA (6-FAM labeled) in the HT29 tumor at 4 h. Green: 6-FAM labeled siRNA; Red: microvasculature; Blue: DAPI stained nuclei. Scale bar, 50 μm. (G) Mice were administered with 40 μg of naked-survivin-siRNA or sCA-survivin-siRNA on days 0, 1, & 2. Tumors were removed on day 3, & western blot analysis for survivin was performed. (H) Many tumor cells treated with sCA-survivin-siRNA (6-FAM labeled) had condensed nuclei & were positive for TUNEL assay. Scale bar, 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25738937), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin regulates autophagic flux. (A) U2OS cells stably expressing survivinWTGFP or GFP alone were treated with RAP (200 nM) & CQ (120 µM) for 2 h, then lysed & immunoblotted with anti-LC3, anti-survivin & anti-tubulin antibodies. Immunoblot shown is representative of four independent experiments. (B) ImageJ quantitation of LC3II signals in (A), normalised against tubulin control & expressed as band intensity relative to untreated GFP cells. (C) Data from (B) expressed as a percentage increase in LC3II between CQ treated & untreated cells to indicate autophagic flux. (D) The above cell lines were treated with CQ (50 µM) for 8 h & p62 levels assessed by immunoblotting at 2 h intervals. Blot shown is representative of three independent experiments. (E) ImageJ quantitation of p62 signals in (D) normalised against tubulin & expressed as band intensity relative to untreated GFP cells. Error bars indicate s.e.m., N=3. *P<0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30348810), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Cdh1 depletion induces early DNA replication. (A) Fzr1+/+ & Fzr1−/− MEFs were synchronized at G1-S phase by double thymidine block (DTB, see diagram). After release from G1-S arrest, cells were collected at the indicated times. Cell extracts were immunoblotted for the indicated proteins. M phase is evaluated by detection of FoxM1 p-T600. beta -actin is shown as a loading control. Asterisk shows the position of Aurora A p-T288. (B) Subcellular colocalization of Aurora B & histone H3 p-S10 in Fzr1+/+ & Fzr1−/− MEFs. Cells were fixed & stained using anti-H3 p-S10 (green) & anti-Aurora B (red) antibodies. Nuclei of the cells were stained using DAPI (blue). Arrowheads show H3 p-S10 in mitotic cells, & arrows show H3 p-S10 in interphase cells. Scale bar: 20 µm. (C) Fzr1+/+ & Fzr1−/− MEFs were fixed & stained using anti-H3 p-S10 (green) & anti-cyclin A (red) antibodies. Nuclei of the cells were stained with DAPI (blue). Cyclin A expression was used as a marker of G2 cells. Scale bar: 10 µm. (D) Fzr1−/− MEFs were treated with the Aurora B specific inhibitor barasertib (10 nM) for 24 h. Cells were fixed & stained using an anti-H3 p-S10 antibody (green). Nuclei of the cells were stained using DAPI (blue). Scale bar: 10 µm. (E) Fzr1+/+ & Fzr1−/− MEFs were serum starved for 72 h, forced to enter the cell cycle after stimulation with 15% FBS & pulsed with EdU. The percentage of EdU-positive cells was scored at different time points. Three independent experiments were used to calculate the mean±s.d. Blots & images in A–D are representative of at least two experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32934012), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Borealin is degraded at G1 phase via APC/CCdh1-mediated polyubiquitylation. (A) 293T cells co-transfected w/ FLAG–Borealin & empty vector (EV), HA–Cdh1, HA–Cdc20, Myc–CUL1, Myc–CUL2, Myc–CUL3, Myc–CUL4, or Myc–CUL5. Then, cells treated w/ 10 µM MG132 for 5 h. Cell extracts immunoprecipitated (IP) w/ an affinity-purified pAb against HA or Myc, & analyzed by immunoblotting as indicated. beta -actin expression used as a loading control. WCE: whole cell extracts. Asterisk indicates non-specific bands. (B) GST-tagged wild-type (WT) borealin bound to glutathione sepharose 4B resin incubated w/ in vitro translated (IVT) Cdh1 for 2 h at 4C. After washing, these proteins eluted & analyzed by immunoblotting using anti-Cdh1 antibody. GST-tagged borealin & GST visualized by Coomassie Blue (CBB) staining. IB, immunoblot. (C) HA-tagged Cdh1 (0, 0.5, 1.0, 1.5 & 2.0 μg) co-transfected w/ FLAG-tagged borealin (0.5 μg) in 293T cells. Cells then collected & lysed for immunoblotting as indicated. beta -actin expression used as a loading control. (D) HeLa cells transfected w/ control or Cdh1 siRNA & synchronized at prometaphase arrest using nocodazole (Noc). After mitotic shake-off, cells released & collected at indicated times. Cell extracts immunoblotted for the indicated proteins. beta -actin expression used as a loading control. (E) An in vivo ubiquitylation assay performed. FLAG-tagged borealin & HA-tagged ubiquitin co-transfected w/ either control, Cdc20 or Cdh1 siRNA in 293T cells. Cell extracts immunoprecipitated using an anti-FLAG antibody, & the precipitates blotted w/ anti-HA & anti-FLAG antibodies. Expression of endogenous Cdc20 & Cdh1 also examined. beta -actin expression used as a loading control. Blots shown representative of two experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32934012), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Borealin is degraded at G1 phase via the ubiquitin–proteasome pathway. (A) HeLa cells were released from a prometaphase arrest with nocodazole (Noc) & collected at the indicated times (left panel). In addition, HeLa cells were synchronized at the G1-S border using a double thymidine block (DTB). After release, cells were collected at the indicated time points (right panel). Cells were then lysed for immunoblotting as indicated. beta -actin expression was used as a loading control. As; asynchronous. (B) The schematic graph shows protein expression level of borealin & APC/C activity during cell-cycle progression, based on the results shown in A. (C) HeLa cells were synchronized in M phase by mitotic shake-off with nocodazole (M). After 2 h release from mitotic arrest (G1), cells were treated with or without 10 μM MG132 or 10 μM lactacystin for 5 h. Asynchronous cells (As) were also treated with or without 10 μM MG132 or 10 μM lactacystin for 5 h. Cells were then collected & lysed for immunoblotting as indicated. beta -actin expression was used as a loading control. Blots shown in A & C are representative of two experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32934012), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Pro-apoptotic activity of SAB-13 & SAB-14. (A–C,E,F), FACS analysis of the cells after 48 h treatment. Analysis of apoptosis induction in 22Rv1 (A) & PC-3 cells (B) using Annexin-V-FITC/propidium iodide (PI) double staining. PC-3 cells were pre-treated with 100 µM of pan-caspase inhibitor z-VAD(OMe)-fmk (zVAD) for 1 h & then treated with indicated concentrations of the drugs for 48 h (B). Viable cells (Annexin-V-FITC(–)/PI(–), LL quadrant) or early apoptotic cells (Annexin-V-FITC(+)/PI(–), LR quadrant) were quantified using the Cell Quest Pro software (C) (mean ± SEM; n = 3; * p < 0.05, Student′s t-test). (D) Western blotting analysis of the protein expression in 22Rv1 cells after 48 h of treatment. beta -actin was used as a loading control (mean ± SEM; n = 3; one-way ANOVA test). Anisomycin (Aniso; treatment with 10 µM for 48 h) was used as a positive control. (E,F) Cell cycle analysis of 22Rv1 cells using PI staining, apoptotic cells were detected as sub-G1 population (E) (mean ± SEM; n = 3; * p < 0.05, one-way ANOVA test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32403427), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Survivin Antibody - BSA Free [NB500-201] - Protein expression pattern of Survivin, XIAP & XAF1 in HCC tissues & non-neoplastic liver parenchyma. IAP members immunoreactivity was estimated by tissue microarray in a subset of HCC patients (n = 40). A-D, Representative Survivin cytoplasmatic immunostaining in a tumor core (A), in a tumor proximal to cirrhosis (C, N: cirrhosis, K: HCC), & in adjacent & long-distance non-neoplastic parenchyma (B & D, respectively). XIAP marked (score 12) & moderate (score 8) immunoreactivity is shown for HCC (E & I, respectively) as well as for cirrhosis (F & L, respectively). G & H, Nuclear XAF1 staining is shown for tumor & non-neoplastic liver whereas XAF1 cytoplasmatic expression in HCC & cirrhosis is shown in panels M & N, respectively. Original magnification ×50 & ×250, for tissue cores & insets, respectively. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-125), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin affects cellular susceptibility to chemotherapeutic drugs(A) siRNA-mediated knockdown of survivin was performed in HCT116 cells for 24 hours (scrambled siRNA (siCtrl) transfection serves as control). Thereafter, cells were treated with 10 μM CPT-11 for 24 hours. Western blot analysis detected protein levels of survivin, p53, as well as cleavage products of caspase-3 & PARP1; vinculin serves as loading control. (B) HCT116 cells were transfected with 0.1 μg & 0.25 μg survivin-MYC plasmid for 24 hours & were treated 5 μM L-OHP for additional 24 & 48 hours. Western blot analysis detected MYC-tag, cleavage of caspase-3 & PARP1; vinculin serves as loading control (n = 2). (C) HCT116 cells were treated with 3 μM ETP-46464 for 1 hour, after which 10 μM CPT-11 were added for additional 24 hours. Western blot was carried out as indicated, with vinculin as loading control (n = 2). (D) HCT116 cells were treated as described in C, but for 48 hours total incubation time. Cells were harvested & analyzed for the occurrence of cells in the subG1 fraction (n=3). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Deficiency of CCAR2 or Hsp60 reduces expression of survivin mRNA. SH-SY5Y (A–E) or BE(2)-M17 cells (E) were transfected with Universal (siU), CCAR2 (siC), or Hsp60 (siH) siRNA. (A,B) Forty-eight hours later, the level of survivin protein was examined by western blotting. Cells deficient in CCAR2 & Hsp60 were treated with 25 μM MG132 (A) or 100 μM chloroquine (B) 4 h or 24 h prior to cell lysis, respectively. (C,D) The level of survivin mRNA in each group of siRNA-transfected cells was measured by RT-PCR. (C) Levels were normalized against beta -actin & quantified using ImageJ software. The relative level of survivin mRNA is expressed as the mean ± standard error of the mean (SEM) (n = 3). Asterisks (*) denote statistically significant differences (p < 0.05, one-way ANOVA). (D) Two different siRNAs targeting CCAR2 & Hsp60 were used to knock down their expressions. (E) The level of each protein was examined by western blotting. The relative level is expressed as the mean ± standard error of the mean (SEM) (n = 3). Indicators (*, #) denote statistically significant differences from the corresponding control cells (p < 0.05, one-way ANOVA). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30609639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Correlation between PARP6 & Survivin expression in CRCA. Expression of PAPR6 & Survivin in 238 CRC cases was examined by immunohistochemistry. Representative images of PARP6, Ki-67 & Survivin in normal colonic mucosa, well differentiated adenocarcinoma & poorly differentiated adenocarcinoma cases. B. Correlation between PARP6 & proliferation marker, Ki-67 in CRC cases by immunohistochemistry. Graph shows Ki-67 index in CRC cases with low or high expression of PARP6. C. Correlation between PARP6 & Survivin in CRC cases by immunohistochemistry. Graph shows Ki-67 index in CRC cases with low or high expression of Survivin. D. The expression of PAPR6 & Survivin were determined in 4 CRC tissues & normal adjacent colorectal tissues by Western blot analysis. beta -actin was used as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26934315), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Proximity Ligation Assay: Survivin Antibody - BSA Free [NB500-201] - NPC-derived EBNA1 is compromised for interaction with SurvivinA. LC-MS analysis of proteins associated with FLAG-EBNA1 (F-EBNA1) from B95-8 or with the NPC DNA binding domain. Unique peptides & spectral counts are shown for USP7, BIRC5 (Survivin), & Tankyrase 1 (TNKS). B. Western blot analysis of FLAG IP from HeLa cells with stable expression of FLAG-vector, F-EBNA1 (B95-8) or F-EBNA1 (NPC) probed with antibody to USP7, Tankyrase 1, Survivin, or FLAG. C. Extracts from stable HeLa cells shown in panel B, were subject to IP with antibody to Survivin probed with antibody to FLAG or Survivin (top panel). Extracts from stable HeLa cells shown in panel B were subject to IP with antibody to Tankyrase 1 probed with antibody to FLAG or Tankyrase1 (lower panel). D. MutuI cell (top panels) or C666-1 cell (lower panels) extracts were subject to IP with antibody to EBNA1 or control IgG, & then assayed by Western blot with antibody to Survivin or EBNA1, as indicated. E. Same as in panel D, except IP with Suvivin or control IgG. F. In situ Proximity Ligation Assay (in situ PLA) is shown for interphase cells from either MUTU-I or C666-1 using mouse anti-EBNA1 & rabbit anti-Survivin. G. Quantification of in situ PLA for n > 100. ** p-value < .01 using student t-test. H. PFGE analysis of EBV episomes & linears at 7 days post-transduction with lentivirus shRNA for shControl or shSurvivin in MUTU I or RAJI cell lines. Human alpha satellite DNA is used for DNA loading control Western blot of Survivin & Actin are shown below for each cell at 7 days post-transduction. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28077791), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - The p53-p21 axis facilitates downregulation of survivin via cell cycle(A) HCT116 wild typeand p21-deficient (p21-/-) cells were treated with 5 μM L-OHP for 24 hours. Whole cell lysates were analyzed with antibodies against p53, p21, & survivin; vinculin serves as loading control. (B) Cell cycle distribution was analyzed after 24 hours treatment by flow cytometry analysis (n = 3). (C) To induce p21, RKO p21ind cells were treated with 3 nM Muristerone A for 24 hours & tested for the levels of p21 & survivin; vinculin, loading control. (D)BIRC5 mRNA levels were analyzed by quantitative real-time PCR after 24 hours treatment with MurA in RKO p21ind cells (n = 3). (E) Cell cycle distribution was measured by flow cytometry analyses of cellular DNA content (n = 3). (F) Scheme summarizing the supposed mechanisms of survivin regulation after L-OHP & CPT-11 treatment. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Apoptosis & survival signaling after L-OHP & CPT-11(A) Western blot analysis using antibodies against p53 & pro-apoptotic BAX & PIG-3 after treatment with 5 μM L-OHP or 10 μM CPT-11. (B) Immunodetection of NF-kappa B p65, RELB & anti-apoptotic survivin, XIAP, BCL-XL & MCL1; vinculin serves as loading control. (C) Effects of increasing doses L-OHP & CPT-11 on caspase-3 & PARP1 cleavage after 24 hours treatment; alpha -tubulin serves as loading control. (D) Cells were treated with a combination of L-OHP & the caspase-inhibitor Z-VAD-FMK (50 μM). Immunodetection of survivin, p53 & full-length caspase-3 was conducted. Detection of apoptosis was determined by cleavage products of caspase-3 & PARP1; beta -actin serves as loading control. Please note: Figure 4A & 4B, as well as Supplementary Figure 2A show signals acquired by different detection methods, but originate from the same Western blots. This is due to a switch in the immunoblot chemiluminescence detection system from X-ray films (darker background) to a CCD camera system (Fusion Solo S, Vilber Lourmat; lighter background). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin is essential for the salinomycin-induced apoptosis in UM cells. a UM cells were treated with salinomycin for 24 h & the protein levels of apoptosis-related proteins were detected by Western blot. b & c UM cells were transduced with lentiviral pTSB-Survivin cDNA (b), Survivin-shRNA constructs (c), or their corresponding empty vectors, & then incubated in the presence of puromycin (1 μg/mL) for 5 days to reach stable clones. Such survivin-manipulated cells were then exposed to salinomycin for 24 h, & subjected to trypan blue exclusion assay (left) & Western blot assay (right). Data represent mean ± SD. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test. d qRT-PCR analysis of BIRC5 mRNA level was done in the 92.1 & Mel270 cells treated with salinomycin for 24 h. **, P < 0.01; ***, P < 0.001, one-way ANOVA, post hoc comparisons, Tukey’s test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31718679), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Survivin Antibody - BSA Free [NB500-201] - Anti-tumor effects & functional evidence of sCA-survivin-siRNA in HCT116 & HT29 solid tumor models.(A) For western blot analysis, HCT116 cells were seeded into 6-well plates & transfected with 100 pmol/well of either control or survivin siRNA by Lp (Lipofectamine 2000) or sCA. Actin blots served as loading controls. (B) For proliferation assays, cells were uniformly seeded into 96-well plates (1 × 104 cells/well), & 5 pmol/well siRNA was used. Cell viability was examined at 48 & 72 h by WST-8 assay. Data represent mean ± SEM. *P = 0.0294, **P = 0.0304 (n = 4, Wilcoxon rank test). (C) In vivo tumor growth. Each vehicle, carrying 15 μg of control siRNA or survivin siRNA, was administered by intravenous injection to mice with HCT116 tumors. Data represent the mean ± SEM (n = 10 tumors, Wilcoxon rank test). (D) Immunostaining of survivin in the tumor tissues on day 19. Scale bar, 50 μm. (E) In vivo live imaging of sCA-siRNA (6-FAM labeled) in HT29 tumor by multiphoton microscopy at 90 min. (F) Fluorescent detection of naked-siRNA (6-FAM labeled) or sCA-siRNA (6-FAM labeled) in the HT29 tumor at 4 h. Green: 6-FAM labeled siRNA; Red: microvasculature; Blue: DAPI stained nuclei. Scale bar, 50 μm. (G) Mice were administered with 40 μg of naked-survivin-siRNA or sCA-survivin-siRNA on days 0, 1, & 2. Tumors were removed on day 3, & western blot analysis for survivin was performed. (H) Many tumor cells treated with sCA-survivin-siRNA (6-FAM labeled) had condensed nuclei & were positive for TUNEL assay. Scale bar, 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25738937), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Survivin was detected in immersion fixed HeLa human cervix adenocarcinoma cell line using Rabbit anti-Survivin Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-201) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells in various stages of mitosis were imaged using a 100X objective and digitally deconvolved.

Survivin was detected in immersion fixed NIH-3T3 Mouse fibroblast cell line using Rabbit anti-Survivin Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-201) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Reactivity:

Hu, Mu, Rt, Ca, Fe, Gp, Ha

Species Glossary

Reactivity: Hu, Mu, Rt, Ca, Fe, Gp, Ha

Applications:

, , , , , , , , ,

Applications: , , , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB500-201AF350
Alexa Fluor 405	NB500-201AF405
Alexa Fluor 488	NB500-201AF488
Alexa Fluor 532	NB500-201AF532
Alexa Fluor 594	NB500-201AF594
Alexa Fluor 647	NB500-201AF647
Alexa Fluor 700	NB500-201AF700
Alexa Fluor 750	NB500-201AF750
Alexa Fluor Plus 405	NB500-201AFP405
Alexa Fluor Plus 488	NB500-201AFP488
Alexa Fluor Plus 555	NB500-201AFP555
Alexa Fluor Plus 594	NB500-201AFP594
Alexa Fluor Plus 647	NB500-201AFP647
Alexa Fluor Plus 680	NB500-201AFP680
Allophycocyanin	NB500-201APC
Biotin	NB500-201B-0.1ml
CoraFluor 1	NB500-201CL1
DyLight 350	NB500-201UV
DyLight 405	NB500-201V-0.1ml
DyLight 488	NB500-201G-0.1ml
DyLight 550	NB500-201R-0.1ml
DyLight 594	NB500-201DL594
DyLight 650	NB500-201C-0.1ml
DyLight 680	NB500-201FR
DyLight 755	NB500-201IR
FITC	NB500-201F-0.1ml
HRP	NB500-201H-0.1ml
Janelia Fluor 525	NB500-201JF525
Janelia Fluor 549	NB500-201JF549
Janelia Fluor 646	NB500-201JF646
Janelia Fluor 669	NB500-201JF669
PE	NB500-201PE
PerCP	NB500-201PCP
mFluor Violet 450 SE	NB500-201MFV450
mFluor Violet 500 SE	NB500-201MFV500
mFluor Violet 610 SE	NB500-201MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB500-201SS

compare

(select up to 3 products from this page to compare)

AF886

Survivin Antibody [Unconjugated]

(2 Reviews)

(107 Publications)

100 μg

AF886

HAF008). A specific band was detected for Survivin at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4." class="big_lightbox">

Western blot shows lysates of MCF-7 human breast cancer cell line and Jurkat human acute T cell leukemia cell line. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (<a class=

HAF008). A specific band was detected for Survivin at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4." alt="Western blot shows lysates of MCF-7 human breast cancer cell line and Jurkat human acute T cell leukemia cell line. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (HAF008). A specific band was detected for Survivin at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4." class="big_thumb" />

VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

Survivin was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (<a class=

VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

CTS013). Tissue was stained with the Anti-Rabbit HRP-DAB Cell & Tissue Staining Kit (brown; CTS005) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." class="big_lightbox">

Survivin was detected in immersion fixed paraffin-embedded sections of human prostate cancer tissue using 10 µg/mL Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886) overnight at 4 °C. Before incubation with the primary antibody tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (<a class=

CTS013). Tissue was stained with the Anti-Rabbit HRP-DAB Cell & Tissue Staining Kit (brown; CTS005) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." class="big_thumb" />

Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C and D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed and -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma and cartilage lysates. For A, B and E the polyclonal rabbit anti-survivin antibody AF886 was used. For C and D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A and C) and 400× (B and D) and 600× (E). Image collected and cropped by CiteAb from the following open publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by R&D Systems.

AB-105-C, open histogram) followed by Phycoerythrin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0110). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules." class="big_lightbox">

Jurkat cells were stained with Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886, filled histogram) or isotype control antibody (Catalog # <a class=NoLineLink href=

AB-105-C, open histogram) followed by Phycoerythrin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0110). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules." class="big_thumb" />

Simple Western lane view shows lysates of Jurkat human acute T cell leukemia cell line and MCF‑7 human breast cancer cell line, loaded at 0.2 mg/mL. A specific band was detected for Survivin at approximately 23 kDa (as indicated) using 5 µg/mL of Rabbit Anti-Human Survivin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF886). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

<b>Biological Strategies Validation. </b>Survivin is required for the proliferation of trophoblastic cells and depletion induces a G2/M arrest.(A) Cell viability assay. JAR (left panel), BeWo (middle panel) and HTR-8/SVneo (HTR, right panel) cells were non-treated (con), treated with either control scrambled siRNA (si con) or siRNA targeting survivin (si survivin) and cell viability was analyzed at indicated time points. Bar: ± SD. (B) Cell cycle profiles. Cells were depleted of survivin for 48 h and cell cycle analysis was performed. con: untreated cells as control. si con: treated with control scrambled siRNA. si survivin: treated with siRNA against survivin. Right panels: quantification of the sub-phases of the cell cycle. (C) Western blot analysis. BeWo cells were transfected with scrambled siRNA (si con) or siRNA targeting survivin (si survivin) for 24 h or 48 h and cellular extracts were prepared for Western blot analysis using indicated antibodies. beta -actin served as loading control. con: non-treated lysates as control. (D) Relative caspase-3/7 activity. The lysates from JAR or BeWo cells treated as in (C) were used for evaluating caspase-3/7 activity. The results are presented as mean ± SD. Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0073337), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Genetic Strategies Validation. </b>ATM and DNA-PKCS induce cell cycle arrest after Survivin-RNAi. a: Western blot analysis of HCT116 and HCT116shATM total cell lysates following Survivin-RNAi (shSurv). Included are shLuc-transduced cells as control. Red values indicate densitometric estimation of protein levels, normalized to Tubulin. b: Indirect immunofluorescence analysis of transduced SBC-2 cells showing colocalisation of activated ATM (ATM S1981) and activated DNA-PK kinase (DNA-PKCS T2609) in shSurv polyploid cells. c: Western blot of HCT116 and HCT116p53−/− cell lysates showing analysis of p53 phosphorylation sites after Survivin knockdown. d: Proposed outline of Survivin RNAi phenotype and the observed DNA-damage response signaling. e: Analysis of HCT116 and HCT116shATM cells transduced with shSurv and combined treatment with DNA-PKCS inhibitor (DNA-PK-I, 10 μM Nu7026) or DMSO. Note combined inhibition of ATM and DNA-PKcs results in a decreased accumulation of p53 and p21waf/cip protein levels and reduction of gamma H2AX levels. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24886358), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin in tubulointerstitial cells.A, Western blot analysis of survivin protein in the renal cortex of wild type and Itga8-/- mice after induction of unilateral ureter obstruction (UUO). B,Exemplary photomicrographs show renal localization of survivin. Itga8+/+, wild type mice; Itga8-/-, Itga8-deficient mice. Data are means±SEM. # p<0.05 UUO versus control (co). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26938996), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Biological Strategies Validation. </b>Inhibition of PI3K gamma attenuates tumor growth in xenograft models associated with infiltrated macrophages.a Experimental procedure illustrating the TG100-115 treatment regimen in BALB/c mice. b CT26 cells (5 × 105 cells/mouse) were subcutaneously injected into the flanks of 6-week-old mice. Mean tumor volume of subcutaneously implanted vehicle- or TG100-115-treated mice (n = 5) and representative images of subcutaneous tumors at day 16 after treatment with vehicle or TG100-115 (box) are shown. c FACS analysis and quantification of CD11b+ F4/80+ (TAM) cell populations in CT26 tumors at day 14 posttreatment (n = 5) and expression levels of MHCII (M1) and CD206 (M2) in CD11b+ F4/80+ cell populations. d Graph showing the percentage of each population (M1, M2) in the vehicle-treated group in comparison with the TG100-115-treated group. e mRNA expression levels of genes involved in the proinflammatory response (il-1 beta , cxcl10) and antiinflammatory response (il-10 and tgf-beta ) were evaluated by real-time PCR in vehicle and TG100-155-treated groups. f Representative western blot analysis showing survival/EMT-related protein expression as well as ERK/AKT-FBW7-MCL-1 signal axis regulation in vehicle- and TG100-155-treated mouse tumor tissues. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

Opposite effects of M1 and M2 macrophages on tumor growth.a Tumor images and b tumor growth 3 weeks after transplantation of HCT116 cells after long-term coculture with differentiated M0, M1, or M2 macrophages (see Materials and Methods). Tumor size was measured 2–3 times a week with a caliper. Tumor volume was calculated using the following formula: tumor volume = (short length × long length × width)/2. The expression of SURVIVIN or p21c) and proliferation markers d in mouse subcutaneous tissues was evaluated by real-time PCR and western blotting, respectively. e Ki67 staining (1:200) of mouse subcutaneous tissues three weeks after subcutaneous injection. Scale bar: 100 μm. The results shown are presented as the mean ± SD from three mice per group. Actin was used as a loading control. *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Biological Strategies Validation. </b>Role of PI3K gamma in TAM-mediated colon cancer cell viability and EMT characteristics.mRNA expression levels of genes involved in the proinflammatory response (IL-1 alpha , IL-1 beta , CXCL10, and IL-8) and antiinflammatory response (IL-10 and CCL17) were evaluated by real-time PCR in M1 a and M2 b macrophages with or without treatment with 10 nm TG100-115 (PI3K gamma inhibitor) for 18 h. c HT29 cells were exposed to TG100-115-treated macrophage CM for 24 h. Cell viability was then measured by WST-1 assay. d Expression levels of apoptosis- and EMT-related markers in CM-treated HT29 cells. CMs were derived from TG100-115 (10 nm)-treated or untreated M0, M1, and M2 macrophages. HT29 cells e and PDCs f were incubated with TG100-115-treated macrophage CM for 24 h. Protein levels of MCL-1 and FBW7 were evaluated using western blotting. Actin was used as a loading control. The results are presented as the mean ± SE. *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Biological Strategies Validation. </b>Analysis for RNA-induced silencing complex cleavage products in treated tumors and immunoblot analysis for target protein complexes and death signals in primary tumors. (A) Total RNA was isolated from tumor tissue and used for 5′ ligation-mediated RACE to determine whether RNA-induced silencing complex (RISC)-mediated cleavage of the transcript occurred. The predicted RACE products are indicated to the right, the size (base pairs (bp)) of the DNA standards shown on the left, and the treatment administered indicated above the lanes. (B) Immunoblot analysis of MDA-MB-231 day 10 tumor lysates following intravenous treatments of 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-siCON1 as indicated above the blots. The signals for three mice per group are shown and the proteins detected are indicated on the right side of the blots. Actin signal was used as the loading control. (C) The protein signals from all mice in each treatment group were quantitated by densitometry using ImageJ software (National Institutes of Health Bethesda, MD, USA). Data presented as mean ± standard error. *P <0.05, **P <0.01. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TBG, tenfibgen. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0524-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Biological Strategies Validation. </b>Ex vivo analysis of the role of macrophage CM in colon cancer patient-derived cells (PDCs).a Estimation of PDC viability after coculture with macrophage CM for 24 h using the WST-1 assay. Error bars are derived from three independent experiments. b Expression levels of apoptosis and EMT markers in macrophage CM-treated PDCs were measured by western blotting. c Wound-healing ability was evaluated by creating wounds on a confluent monolayer of PDCs using 1-Dish 35-mm-high culture inserts. d Activation of AKT and ERK and expression levels of MCL-1 and FBW7 assessed by western blotting. Actin was used as a loading control. The results are presented as the mean ± SE. **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32444799), licensed under a CC-BY license. Not internally tested by R&D Systems.

$<b>Biological Strategies Validation. </b>Response over time to TBG-RNAi-CK2 treatment in PC3-LN4 xenograft tumors(A) Verification of nuclear and cytosol protein fractionation from tumor tissue is shown by comparative immunoblot analysis of CK2 alpha alpha ′, lamin A/C, ERp72, and actin. T1, T2, and T3 labels indicate different tumors. Antibody sourcing information is listed in Materials and Methods. (B) Immunoblot analysis of fractionated PC3-LN4 tumor lysates following intravenous treatments of 0.01 mg/kg TBG-RNAi-CK2 or TBG-RNAi-F7 as indicated above the blots. The signals for three mice per group are shown, the proteins detected are indicated on the right, and the cell fraction and size markers are indicated on the left. Actin signal was used as the loading control. T1, T2, and T3 labels indicate different tumors within each treatment group. Antibody sourcing information is listed in Materials and Methods. (C) The percentage of Ki-67-positive tumor cells was determined from Ki-67-stained tumor sections. The percentage of Ki-67-positive cells on each day was expressed relative to day 5 (setting day 5 as 100%) and is shown graphically for each treatment. Mean and standard deviation are shown. Sample sizes: n = 6 for all groups except n = 7 for TBG-RNAi-F7 day 7. Image collected and cropped by CiteAb from the following open publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11442), licensed under a CC-BY license. Not internally tested by R&D Systems.$

Immunoblot analyses following small interfering RNA-mediated downregulation of CDK11 and CK2 in breast cancer cells. Immunoblot analysis of MDA-MB-231 and SUM-149 cell lysates following small interfering RNA (siRNA) transfection. Transfected siRNAs are indicated above the blots, proteins detected are indicated on the right side of the blots. CDK11p110, cyclin L1 alpha , cyclin L2 alpha , and CK2 alpha alpha ′ beta lysates are 72 hours post transfection; caspase 3, Bcl-xL, and survivin lysates are 96 hours post transfection. Actin signal was used as the loading control. CDK, cyclin-dependent kinase; CK2, casein kinase 2. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0524-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

BV6 considerably reduces expression of IAP proteins. SW480, HT-29 and HCT-15 cells were plated in a 3D laminin-rich extracellular matrix and treated with 1 μM BV6 or DMSO control 4 h before irradiation with 4 Gy. At different time points, expression of indicated proteins was analyzed by Western blotting, while beta -actin served as loading control. Two independent experiments were performed with similar results Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26383618), licensed under a CC-BY license. Not internally tested by R&D Systems.

Effects of BA and irradiation on protein expression levels of glioma cells. BA treatment affects the cleavage of PARP, the expression of survivin and hypoxia-induced HIF-1 alpha protein levels in U251MG (left) and U343MG (right) cells. Cell lines were untreated (UT), treated with DMSO or with increasing doses of BA from 10, 20 or 25 μM under normoxic conditions (A, B) and untreated (UT), treated with DMSO or with doses of 10 or 15 μM BA plus irradiation at 15 Gy under hypoxic conditions (C, D). Actin served as an internal loading control. The Western blot shows one representative result out of three independent experiments. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/21906280), licensed under a CC-BY license. Not internally tested by R&D Systems.

IGF-I induces Survivin through a Smad dependent mechanism.(A) NRP-152 cells plated overnight in GM3 were treated at various times with LR3-IGF-I for up to 72 h, and cell lysates were analyzed for Western blot expression of Survivin, and P-Smads 2 and 3. (B) NRP-152 cells stably expressing sh-Smads 2, 3, and 2+3 or lentiviral sh-LacZ (control) were treated with 2 nM LR3-IGF-I or vehicle for 24 h prior to Western blot analysis for Survivin and Smads 2 and 3. (C) NRP-152 cells stably expressing sh-Smads 2+3 or lentiviral sh-LacZ (control) were treated with DMSO vehicle or 10 µM SB431542 for 2 h prior to treatment with 2 nM LR3-IGF-I or vehicle for 24 h, and changes in Survivin expression was assessed by Western blot analysis. (D) NRP-152 cells were treated with either 10 µM HTS466284 or 10 µM SB43152 for 2 h prior to treatment with 2 nM LR3-IGF-I or vehicle for 24 h, and changes in Survivin expression were assessed by Western blot analysis. (E,F) RWPE-1 and VCaP cells plated in GM3 were treated with LR3-IGF-I and the TGF-beta receptor kinase inhibitors HTS466284 (HTS) or TKDI for 24 h prior to lysing cells for Western blot analysis of Survivin expression. Results are representative of two to three separate experiments. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/23658701), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western blot analyses following treatment of PC-3 cells with AHC compounds.Western blot analysis of cellular lysates prepared from PC-3 cells treated with 7-O-galloyl catechin (GC), catechin (C), catechin gallate (CG), methyl gallate (MG), or equal dilution of DMSO was performed. Treatments are indicated above the blots. The protein detected is indicated to the left of each blot, and the size of protein detected is indicated to the right of each blot. The quantitation of the data is shown in Supplementary Table 2. Cropped blots are shown. Full sized blots are included in Supplementary Fig. 3. All gels and blots were run under the same experimental conditions as described in Methods. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26975752), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western blot analyses following treatment of MDA-MB-231 cells with AHC compounds.Western blot analysis of cellular lysates prepared from MDA-MB-231 cells treated with 2 concentrations each of catechin gallate (CG) and methyl gallate (MG), or dilution of DMSO representing the highest concentration was performed. Treatments are indicated above the blots. The protein detected is indicated to the left of each blot, and the size of protein detected is indicated to the right of each blot. The quantitation of the data is shown in Supplementary Table 3. Cropped blots are shown. Full sized blots are included in Supplementary Fig. 4. All gels and blots were run under the same experimental conditions as described in Methods. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26975752), licensed under a CC-BY license. Not internally tested by R&D Systems.

Validation of NF-kappa B activation in RH30 cells and spheroids. Western blot analysis showing BV6-induced changes in IAP protein levels in RH30 cells cultured in monolayer cultures (A) or as spheroids (B). BV6-regulated canonical and non-canonical NF-kappa B signaling pathways in RH30 cells cultured in monolayer cultures (C) or as spheroids (D). Western blots are exemplary of at least two independent experiments. If applicable, Western blot quantification is depicted as fold changes of GAPDH-normalized target protein expression using the untreated condition as reference. * depicts unspecific signal. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36980247), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunoblot analysis of CK2 downregulation and chemical inhibition in PC3-LN4 cells. A Upper panel: Immunoblot analysis following siRNA transfection (48 h). Proteins detected are indicated on the right side of the blots. Actin signal was used as the loading control. Lower panel: Chart representing quantitation of protein signals relative to si-Ctrl treatment. Data points from 2 biological experiments. siCtrl = siRNA for non-targeting control. Antibodies: CK2 alpha (A300-197A); CK2 alpha ΄ (A300-199A); CK2 beta (sc-46666); Actin (sc-1616). B Representative immunoblot analysis following TBB small molecule anti-CK2 inhibitor treatment (48 h). Proteins detected are indicated on the right side of the blots. Actin signal was used as the loading control. Antibodies: CK2 alpha (A300-197A); CK2 alpha ΄ (A1616); CK2 beta (sc-46666); Survivin (AF886); Actin (sc-1616). Lower panel: Chart representing quantitation of protein signals relative to si-Ctrl treatment. Vertical lines indicate removal of lanes. Data points from 2 experimental replicates per cell line Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/39394061), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF886U-100UG
Alexa Fluor 405	AF886V-100UG
Alexa Fluor 488	AF886G-100UG
Alexa Fluor 532	AF886X-100UG
Alexa Fluor 594	AF886T-100UG
Alexa Fluor 647	AF886R-100UG
Alexa Fluor 700	AF886N-100UG
Alexa Fluor 750	AF886S-100UG
Alexa Fluor Plus 405	AF886AFP405-100UG
Alexa Fluor Plus 488	AF886AFP488-100UG
Alexa Fluor Plus 555	AF886AFP555-100UG
Alexa Fluor Plus 594	AF886AFP594-100UG
Alexa Fluor Plus 647	AF886AFP647-100UG
Alexa Fluor Plus 680	AF886AFP680-100UG
Allophycocyanin	AF886A
Biotin	AF886B
CoraFluor 1	AF886CL1
DyLight 350	AF886D
DyLight 405	AF886E
DyLight 488	AF886K
DyLight 550	AF886L
DyLight 594	AF886M
DyLight 650	AF886W
DyLight 680	AF886Y
DyLight 755	AF886Z
FITC	AF886F
HRP	AF886H
Janelia Fluor 525	AF886JF525
Janelia Fluor 549	AF886I
Janelia Fluor 646	AF886J
Janelia Fluor 669	AF886JF669
PE	AF886P
PerCP	AF886C
mFluor Violet 450 SE	AF886MFV450
mFluor Violet 500 SE	AF886MFV500
mFluor Violet 610 SE	AF886MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF886-SP

compare

(select up to 3 products from this page to compare)

NB500-238

Survivin Antibody (60.11) - BSA Free

(3 Reviews)

(43 Publications)

0.1 ml

NB500-238

Western Blot: Survivin Antibody (60.11) [NB500-238] - Survivin detection in 30ug of HeLa whole cell extract using [NB500-238] at 1ug/ml. Detected at predicted molecular weight of 16 kDa.

<b>Genetic Strategies Validation. </b>Survivin-Antibody-60-11-Knockdown-Validated-NB500-238-img0020.jpg

Immunocytochemistry/Immunofluorescence: Survivin Antibody (60.11) [NB500-238] - HeLa cells stained NB500-205 (Green) detected with DyLight Fluor 488 conjugated anti-mouse IgG secondary antibody. Nuclei are counterstained with Hoechst 33258 (Blue). Image using the Unpurified format of this antibody.

Immunohistochemistry-Paraffin: Survivin Antibody (60.11) [NB500-238] - Staining of ovary cancer. Image using the Unpurified format of this antibody.

Flow Cytometry: Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on U2OS cells with Survivin Antibody (60.11) [NB500-238AF700] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.

Flow (Intracellular): Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on Daudi cells with Survivin Antibody (60.11)[NB500-238] (blue) and a matched isotype control, Mouse IgG2a Kappa Light Chain Isotype Control (MG2a-53) [NB600-986] (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).

Binding of antibody (60.11) used in imaging flow cytometry to full-length survivin protein and to survivin vaccine peptide aa53-67/M57 and wild type peptide aa53-67

A431 human skin carcinoma cell line was stained with Mouse anti-Survivin (60.11) Protein-G purified Monoclonal Antibody conjugated to Alexa Fluor® 647 (Catalog # NB500-238AF647, blue histogram) or matched control antibody (orange histogram).

Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - Binding of antibody (60.11) used in imaging flow cytometry to full-length survivin protein & to survivin vaccine peptide aa53-67/M57 & wild type peptide aa53-67 Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.21773), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - CD133+ cells are more resistant to chemotherapeutic agents. STA-ET-8.2 cells were FACS-sorted & CD133+ & CD133- fractions treated with increasing concentrations of (A) Doxorubicin (Doxo), (B) Etoposide (Etop), (C) Vincristine (Vinc) or (D) a combination of all three drugs at high (Doxo 10 μM; Etop 10 ug/ml; Vinc 100 ng/ml), medium (Doxo 2.5 μM; 20 Etop 2.5 ug/ml; Vinc 25 ng/ml) & low (Doxo 0.5 μM; Etop 0.5 ug/ml; Vinc5 ng/ml) concentrations. Viability was assessed by MTS assay after 96 hrs (*p < 0.05) & CD133+ cells displayed increased drug resistance. (E): CD133+ & CD133- TC-71 cells are equally sensitive to Doxo, Etop, & Vinc. (F): Western blot reveals no difference in apoptosis & drug resistance protein expression between unsorted & CD133-sorted STA-ET-8.2 cell fractions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/20346143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB500-238AF350
Alexa Fluor 405	NB500-238AF405
Alexa Fluor 488	NB500-238AF488
Alexa Fluor 532	NB500-238AF532
Alexa Fluor 594	NB500-238AF594
Alexa Fluor 647	NB500-238AF647
Alexa Fluor 700	NB500-238AF700
Alexa Fluor 750	NB500-238AF750
Alexa Fluor Plus 405	NB500-238AFP405
Alexa Fluor Plus 488	NB500-238AFP488
Alexa Fluor Plus 555	NB500-238AFP555
Alexa Fluor Plus 594	NB500-238AFP594
Alexa Fluor Plus 647	NB500-238AFP647
Alexa Fluor Plus 680	NB500-238AFP680
Allophycocyanin	NB500-238APC
Biotin	NB500-238B
CoraFluor 1	NB500-238CL1
DyLight 350	NB500-238UV
DyLight 405	NB500-238V
DyLight 488	NB500-238G
DyLight 550	NB500-238R
DyLight 594	NB500-238DL594
DyLight 650	NB500-238C
DyLight 680	NB500-238FR
DyLight 755	NB500-238IR
FITC	NB500-238F
HRP	NB500-238H
Janelia Fluor 525	NB500-238JF525
Janelia Fluor 549	NB500-238JF549
Janelia Fluor 646	NB500-238JF646
Janelia Fluor 669	NB500-238JF669
PE	NB500-238PE
PerCP	NB500-238PCP
mFluor Violet 450 SE	NB500-238MFV450
mFluor Violet 500 SE	NB500-238MFV500
mFluor Violet 610 SE	NB500-238MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB500-205
BSA Free	NB500-205SS
BSA Free	NB500-238SS
Azide and BSA Free	NBP2-80969

compare

(select up to 3 products from this page to compare)

NB500-644

Survivin Antibody (8E2) - BSA Free

(15 Publications)

0.1 ml

NB500-644

Flow (Intracellular): Survivin Antibody (8E2) [NB500-644] - An intracellular stain was performed on Daudi cells with Survivin Antibody (8E2) [NB500-644] (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).

An intracellular stain was performed on U-2 OS human osteosarcoma cell line with Mouse anti-Survivin (8E2) Protein-G purified Monoclonal Antibody conjugated to Phycoerythrin (Catalog # NB500-644PE, blue histogram) or matched control antibody (orange histogram) at 2.5 µg/mL for 30 minutes at RT.

Reactivity:

Hu, Rt

Species Glossary

Reactivity: Hu, Rt

Applications:

, , , , ,

Applications: , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB500-644AF350
Alexa Fluor 405	NB500-644AF405
Alexa Fluor 488	NB500-644AF488
Alexa Fluor 532	NB500-644AF532
Alexa Fluor 594	NB500-644AF594
Alexa Fluor 647	NB500-644AF647
Alexa Fluor 700	NB500-644AF700
Alexa Fluor 750	NB500-644AF750
Alexa Fluor Plus 405	NB500-644AFP405
Alexa Fluor Plus 488	NB500-644AFP488
Alexa Fluor Plus 555	NB500-644AFP555
Alexa Fluor Plus 594	NB500-644AFP594
Alexa Fluor Plus 647	NB500-644AFP647
Alexa Fluor Plus 680	NB500-644AFP680
Allophycocyanin	NB500-644APC
Biotin	NB500-644B
CoraFluor 1	NB500-644CL1
DyLight 350	NB500-644UV
DyLight 405	NB500-644V
DyLight 488	NB500-644G
DyLight 550	NB500-644R
DyLight 594	NB500-644DL594
DyLight 650	NB500-644C
DyLight 680	NB500-644FR
DyLight 755	NB500-644IR
FITC	NB500-644F
HRP	NB500-644H
Janelia Fluor 525	NB500-644JF525
Janelia Fluor 549	NB500-644JF549
Janelia Fluor 646	NB500-644JF646
Janelia Fluor 669	NB500-644JF669
PE	NB500-644PE
PerCP	NB500-644PCP
mFluor Violet 450 SE	NB500-644MFV450
mFluor Violet 500 SE	NB500-644MFV500
mFluor Violet 610 SE	NB500-644MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB500-644SS
Azide and BSA Free	NBP2-80970

compare

(select up to 3 products from this page to compare)

NB500-236

Survivin [p Thr34] Antibody - BSA Free

(1 Review)

(10 Publications)

0.1 ml

NB500-236

<b>Biological Strategies Validation. </b>nb500-236_rabbit-polyclonal-survivin-p-thr34-antibody-2552023151499.jpg

Western Blot: Survivin [p Thr34] Antibody [NB500-236] - Combination therapy with TiOxNPs & IR suppressed the aggressiveness of xenografts in dissociated MIA PaCa sphere cell-bearing mice. A HE staining & IHC analysis of p-H2AX, c-caspase-3, ki67, PCNA, snail/Slug, & vimentin in the indicated groups. Scale bar = 50 μm. n=5. B Western blot for expression of p-H2AX, c-caspase-3, p-survivin, snail/Slug, & vimentin in xenografts of dissociated MIA PaCa sphere-bearing cells treated with TiOxNPs and/or irradiation. C In vivo apoptosis marker TUNEL assay in xenografts of dissociated MIA PaCa sphere-bearing cells treated with TiOxNPs and/or irradiation. n=5. Data are shown as the mean ± standard deviation. ns, not significant. ****p < 0.0001. Scale bar = 200 μm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35428310), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Survivin [p Thr34] was detected in immersion fixed HeLa human cervix adenocarcinoma cell line using Rabbit anti-Survivin [p Thr34] Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-236) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Survivin [p Thr34] was detected in immersion fixed NIH-3T3 Mouse fibroblast cell line using Rabbit anti Survivin [p Thr34] Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-236) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells in various stages of mitosis were imaged using a 100X objective and digitally deconvolved.

Reactivity:

Hu, Mu, Po, Bv, Ca, Fe, Pm

Species Glossary

Reactivity: Hu, Mu, Po, Bv, Ca, Fe, Pm

Applications:

,

Applications: ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB500-236AF350
Alexa Fluor 405	NB500-236AF405
Alexa Fluor 488	NB500-236AF488
Alexa Fluor 532	NB500-236AF532
Alexa Fluor 594	NB500-236AF594
Alexa Fluor 647	NB500-236AF647
Alexa Fluor 700	NB500-236AF700
Alexa Fluor 750	NB500-236AF750
Alexa Fluor Plus 405	NB500-236AFP405
Alexa Fluor Plus 488	NB500-236AFP488
Alexa Fluor Plus 555	NB500-236AFP555
Alexa Fluor Plus 594	NB500-236AFP594
Alexa Fluor Plus 647	NB500-236AFP647
Alexa Fluor Plus 680	NB500-236AFP680
Allophycocyanin	NB500-236APC
Biotin	NB500-236B
CoraFluor 1	NB500-236CL1
DyLight 350	NB500-236UV
DyLight 405	NB500-236V
DyLight 488	NB500-236G
DyLight 550	NB500-236R
DyLight 594	NB500-236DL594
DyLight 650	NB500-236C
DyLight 680	NB500-236FR
DyLight 755	NB500-236IR
FITC	NB500-236F
HRP	NB500-236H
Janelia Fluor 525	NB500-236JF525
Janelia Fluor 549	NB500-236JF549
Janelia Fluor 646	NB500-236JF646
Janelia Fluor 669	NB500-236JF669
PE	NB500-236PE
PerCP	NB500-236PCP
mFluor Violet 450 SE	NB500-236MFV450
mFluor Violet 500 SE	NB500-236MFV500
mFluor Violet 610 SE	NB500-236MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB500-236SS

compare

(select up to 3 products from this page to compare)

NB500-237

Survivin Antibody (32.1) - BSA Free

(12 Publications)

0.1 ml

NB500-237

Immunohistochemistry-Paraffin: Survivin Antibody (32.1) [NB500-237] - Immunohistochemical staining of formalin-fixed paraffin-embedded human lung cancer tissue using Survivin Antibody (32.1) [NB500-237].

Western Blot: Survivin Antibody (32.1) - BSA Free [NB500-237] - Survivin expression in human chondrosarcoma. Immunohistochemistry & immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C & D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed & -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma & cartilage lysates. For A, B & E the polyclonal rabbit anti-survivin antibody AF886 was used. For C & D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A & C) & 400× (B & D) & 600× (E). Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Survivin (32.1) was detected in immersion fixed U-2 OS human osteosarcoma cell line using Mouse anti-Survivin (32.1) Protein G Purified Monoclonal Antibody conjugated to FITC (Catalog # NB500-237F) (green) at 10 µg/mL overnight at 4C. Cells were counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Reactivity:

Hu, Ha

Species Glossary

Reactivity: Hu, Ha

Applications:

, , , , ,

Applications: , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB500-237AF350
Alexa Fluor 405	NB500-237AF405
Alexa Fluor 488	NB500-237AF488
Alexa Fluor 532	NB500-237AF532
Alexa Fluor 594	NB500-237AF594
Alexa Fluor 647	NB500-237AF647
Alexa Fluor 700	NB500-237AF700
Alexa Fluor 750	NB500-237AF750
Alexa Fluor Plus 405	NB500-237AFP405
Alexa Fluor Plus 488	NB500-237AFP488
Alexa Fluor Plus 555	NB500-237AFP555
Alexa Fluor Plus 594	NB500-237AFP594
Alexa Fluor Plus 647	NB500-237AFP647
Alexa Fluor Plus 680	NB500-237AFP680
Allophycocyanin	NB500-237APC
Biotin	NB500-237B
CoraFluor 1	NB500-237CL1
DyLight 350	NB500-237UV
DyLight 405	NB500-237V
DyLight 488	NB500-237G
DyLight 550	NB500-237R
DyLight 594	NB500-237DL594
DyLight 650	NB500-237C
DyLight 680	NB500-237FR
DyLight 755	NB500-237IR
FITC	NB500-237F
HRP	NB500-237H
Janelia Fluor 525	NB500-237JF525
Janelia Fluor 549	NB500-237JF549
Janelia Fluor 646	NB500-237JF646
Janelia Fluor 669	NB500-237JF669
PE	NB500-237PE
PerCP	NB500-237PCP
mFluor Violet 450 SE	NB500-237MFV450
mFluor Violet 500 SE	NB500-237MFV500
mFluor Violet 610 SE	NB500-237MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB500-237SS
Azide and BSA Free	NBP2-80968

compare

(select up to 3 products from this page to compare)

NB100-56167

Survivin Antibody - BSA Free

(6 Publications)

0.05 ml

NB100-56167

Immunohistochemistry: Survivin Antibody [NB100-56167] - Immunohistochemical analysis of Survivin in formalin-fixed paraffin-embedded human prostate and breast cancer using Survivin Antibody [NB100-56167]. A and A1, prostate cancer at low and high magnification, respectively. B and B1, breast cancer. B1 is a high magnification of an area of metastasis. Hematoxylin-eosin counterstain.

Immunohistochemistry-Paraffin: Survivin Antibody [NB100-56167] - Analysis of Survivin in a formalin-fixed paraffin-embedded human brain tissue microarray using Survivin Antibody [NB100-56167]. A. Differential expression of Survivin in brain tumors from six different patients. A1-A3, high magnification from A. A1, gemistocytic astrocytoma. A2, medulloblastoma. A3, choroid plexus papilloma. Hematoxylin-eosin counterstain.

Survivin was detected in immersion fixed HeLa human cervix adenocarcinoma cell line using Rabbit anti-Survivin Whole Serum (Catalog # NB100-56167) at a 1:500 dilution overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Survivin was detected in immersion fixed CHO-K1 Chinese hamster ovary epithelium cell line using Rabbit anti-Survivin Whole Serum (Catalog # NB100-56167) at a 1:500 dilution overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Representative Western blots showing the IAP levels in EV derived from individual European American (EA) (N1-N5) & (N7-N9), *N6 and African American (AA) (N1-N9) patients with prostate cancer (PCa).Specific antibodies against Survivin, XIAP, cIAP-1, cIAP-2, and Lamp1 were used for the Western blotting analysis of total exosomal proteins. The blots from both patient groups were processed under identical conditions; Lamp 1 was used as loading control. (*N6, Hispanic.) (Both blots were done side by side in the same gel running and transferring apparatus, blocking, washing buffers, and antibody incubations were done in the same time, in the same incubating trays under the identical exposure to keep the consistencies.) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28981528), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Ma, Po, Bv, Ca, Fe, Pm-Or

Species Glossary

Reactivity: Hu, Mu, Rt, Ma, Po, Bv, Ca, Fe, Pm-Or

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Alt Catalog#

IMG-5754

Alt Catalog# IMG-5754

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-56167SS

compare

(select up to 3 products from this page to compare)

NB110-92717

Survivin [p Ser20] Antibody - BSA Free

(5 Publications)

0.1 ml

NB110-92717

Silencing or inhibition of PLK1 and AURKB modulates survivin phosphorylation at S20 and T117 in AA TNBC cells.A, B Immunoblots showing the levels of PLK1, survivin, p-survivin (S20), and beta -actin after PLK1 silencing (A, B) or inhibition (C) in AA and EA TNBC cell lines. D–F Immunoblots showing the levels of AURKB, survivin, p-survivin (T117), and beta -actin after AURKB silencing (D, E), or inhibition (F) in AA and EA TNBC cell lines. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36627281), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

CPC complex formation is highest in S20-T117 double phospho-mimic survivin mutants.A Schematic representation of survivin-mutant plasmids. B–D Immunoblots (B, C) showing the levels of CPC proteins in input (B) and IP-bound (C) samples from cells expressing various survivin-WT and mutant plasmids, and their respective quantification (D). E Bar graphs showing the percentage of cell proliferation in control cells and in cells expressing survivin-WT and mutant plasmids. F Schematic illustration of YM155 treatment schedule in mice bearing tumors and surgically implanted with osmotic pumps. G–J Representative tumor images (G), changes in tumor volume (H), and changes in tumor size (I, J) in mice bearing AA (n = 12) and EA (n = 12) TNBC xenografts. Bars represent mean +/- SEM. Unpaired two-tailed Student’s t-test with Welch’s correction was used to determine statistical significance (*P < 0.05, **P < 0.005, ns = non-significant). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36627281), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, ,

Applications: , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB110-92717AF350
Alexa Fluor 405	NB110-92717AF405
Alexa Fluor 488	NB110-92717AF488
Alexa Fluor 532	NB110-92717AF532
Alexa Fluor 594	NB110-92717AF594
Alexa Fluor 647	NB110-92717AF647
Alexa Fluor 700	NB110-92717AF700
Alexa Fluor 750	NB110-92717AF750
Alexa Fluor Plus 405	NB110-92717AFP405
Alexa Fluor Plus 488	NB110-92717AFP488
Alexa Fluor Plus 555	NB110-92717AFP555
Alexa Fluor Plus 594	NB110-92717AFP594
Alexa Fluor Plus 647	NB110-92717AFP647
Alexa Fluor Plus 680	NB110-92717AFP680
Allophycocyanin	NB110-92717APC
Biotin	NB110-92717B
CoraFluor 1	NB110-92717CL1
DyLight 350	NB110-92717UV
DyLight 405	NB110-92717V
DyLight 488	NB110-92717G
DyLight 550	NB110-92717R
DyLight 594	NB110-92717DL594
DyLight 650	NB110-92717C
DyLight 680	NB110-92717FR
DyLight 755	NB110-92717IR
FITC	NB110-92717F
HRP	NB110-92717H
Janelia Fluor 525	NB110-92717JF525
Janelia Fluor 549	NB110-92717JF549
Janelia Fluor 646	NB110-92717JF646
Janelia Fluor 669	NB110-92717JF669
PE	NB110-92717PE
PerCP	NB110-92717PCP
mFluor Violet 450 SE	NB110-92717MFV450
mFluor Violet 500 SE	NB110-92717MFV500
mFluor Violet 610 SE	NB110-92717MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB110-92717SS

compare

(select up to 3 products from this page to compare)

NB100-911

Survivin Antibody Pack

(7 Publications)

5 Vials

NB100-911

<b>Genetic Strategies Validation. </b>Western Blot: Survivin Antibody Pack [NB100-911] - Suppression of survivin expression by transfection of siRNA. RNA interference was performed in SW1353 and Hs 819.T, either for GFP as control or for survivin. A: A pronounced decrease of survivin protein levels was measured by immunoblotting in SW1353 and Hs819.T. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Survivin Antibody (60.11) [NB500-238]

Immunocytochemistry/Immunofluorescence: Survivin Antibody Pack [NB100-911] - Analysis using the HRP conjugate of [NB500-201]. Staining of Telophase with accumulation of survivin in the midbodies of two daughter cells. Survivin detection using [NB500-201].

<b>Independent Antibodies Validation. </b>Survivin-Antibody-Pack-Immunohistochemistry-NB100-911-img0005.jpg

Immunohistochemistry-Paraffin: Survivin Antibody Pack [NB100-911] - Immunohistochemical staining of formalin-fixed paraffin-embedded human lung cancer tissue using Survivin Antibody (32.1) [NB500-237].

Reactivity:

Hu, Mu

Species Glossary

Reactivity: Hu, Mu

Applications:

, , , ,

Applications: , , , ,

Validated by:

Validated by:

compare

(select up to 3 products from this page to compare)

MAB886

Survivin Antibody (91630) [Unconjugated]

(7 Publications)

100 μg

MAB886

MAB002, open histogram) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules." class="big_lightbox">

MAB002, open histogram) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules." alt="Jurkat cells were stained with Mouse Anti-Human Survivin Monoclonal Antibody (Catalog # MAB886, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules." class="big_thumb" />

Exposure to survivin enriched PD-1+ Bcl-6+ subset of Tfh via STAT3 dependent mechanismsDBA/1 mice were immunized with survivin-derived peptide (100 μg/mouse × 4, subcutaneously). Control mice were immunized with ovalbumin-derived peptide (OVA). Both groups were then subjected to collagen-induced arthritis. Anti-survivin IgG antibodies, anti-Fcg antibodies, & survivin levels in serum were measured by ELISA A. Flow cytometry analysis of the expression of survivin B. in CD44hiCD4+ lymphocytes, & expression of PD-1 C. & Bcl-6 E. in survivin+CXCR5+ CD4+ lymphocytes in spleen (SPL) & lymph nodes (LN). PD-1 expression correlated to the size of CXCR5+survivin+ population D. Dots represent individual mice & the horizontal line shows median of the group. Protein levels of active STAT3 phosphorylated at Y705 (pStat3), total Stat3, Bcl-6 & actin in spleen were analyzed by the Western blot F. The levels of each protein were quantified in ratio to actin of each sample. Quantification of the detected bands is presented as box plots. Transcription of Bcl-6, cMaf & IL-21 in the spleen was analyzed by RT-PCR & presented in relative quantity (RQ) to the median of the control group G. Anti-survivin antibodies in serum correlated with the size of survivin+ CD4 population in spleen of survivin-immunized mice H. Comparison of the correlations in the survivin- & OVA-immunized groups is done by the Fisher r-to-z transformation analysis. Anti-Fcg antibodies correlated with the intensity of PD-1 on CXCR5+survivin+ CD4 lymphocytes I., as measured by flow cytometry. Box plots with line represent IQR of the group & median, respectively, & error lines indicate min & max values. The Mann-Whitney U-test was used to compare differences between groups. Correlation analyses were performed using Spearman's test. Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26343374), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin positive subset of CD44hi CD4 lymphocytes in mouse possess a complete phenotype of Tfh cells Spleen and lymph nodes from collagen II immunized arthritic (CIA) mice were analyzed for expression of survivin and Bcl-6 using flow cytometry A. Cells were gated on memory CD44hiCD4+ lymphocytes. Expression of CXCR5 B. and PD-1 C. was investigated within Bcl-6+ survivin+ and Bcl-6− survivin+ cells. Dots represent individual mice and the horizontal line shows median of the group. Survivin translation in CIA mice was inhibited by shRNA-producing constructs provided as a single intra-peritoneal injection (shSurv16, n = 10, or shSurv13+16, n = 10). Control mice were treated with a non-targeting RNA construct (shNT, n = 9). Survivin expression in spleen was analyzed by flow cytometry 12 days after the injection. Cells were gated on CD4+ lymphocytes. Intensity of survivin expression (MFI) within the groups is shown by a representative histogram and summarized in a box plot D. Survivin expression (MFI) on CD4 lymphocytes correlated to the size of CD44hiCD62L+ population E. Expression of CXCR5 on CD44hiCD4+ lymphocytes in the groups is shown as box plot F. CXCR5+ population correlates with the intensity of survivin G. and with Bcl-6 mRNA H. Boxes and lines represent IQR and median, respectively, and error lines indicate min and max values. The Mann-Whitney U-test was used to compare differences between groups. Correlation analyses were performed using Spearman's test. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26343374), licensed under a CC-BY license. Not internally tested by R&D Systems.

Survivin expression is an essential feature of human CXCR5+ Tfh cell phenotypeIntracellular expression of survivin was investigated in memory (CD45RA−) or naïve (CD45RA+) CD4+ T cells of RA patients (n = 21) and healthy controls (n = 10) using flow cytometry. Cells are gated on CD4+ lymphocytes. Box plots show the frequency of survivin+ cells A. and the mean fluorescence intensity (MFI) of survivin B. Expression of CXCR5 C. within survivin+ and survivin− CD4+ cells, and Bcl-6 D. within survivin+ and survivin− memory (CD45RA−) CD4+ cells of RA patients. The intensity of survivin expression E. within Bcl-6+ and Bcl-6− survivin+ CXCR5+ CD4 cells. The Mann-Whitney U-test was used to compare differences between groups. PBMCs of healthy subjects (1 × 106/ml, n = 6) were cultured with anti-CD3 (0.25 μg/ml) alone or in combination with IL-12 (20 ng/ml) or IL-21 (50 ng/ml). On day 5, the formation of Tfh cells was recognized by expression of CXCR5 and intracellular production of IL-21. Cells were gated on viable CD4+ lymphocytes. Intensity of CXCR5 expression on survivin+ CD4 cells is shown F. The frequency of CXCR5+ cells within survivin+ and survivin− CD4 subsets stimulated with alpha CD3 + IL-12 G. Intracellular production of IL-21 within the CXCR5+survivin+ and CXCR5+survivin− CD4 cells stimulated with alpha CD3 + IL-12 is shown by histogram H. Frequency of PD-1+ IL-21+ cells is shown by box plots I. The Wilcoxon matched-pairs signed rank test to compare differences. Boxes and lines represent IQR and median, respectively, and error lines indicate min and max values. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26343374), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

,

Applications: ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	IC886U-100UG
Alexa Fluor 405	IC886V-100UG
Alexa Fluor 488	IC886G-100UG
Alexa Fluor 532	FAB886X
Alexa Fluor 594	IC886T-100UG
Alexa Fluor 647	IC886R-100UG
Alexa Fluor 700	IC886N-100UG
Alexa Fluor 750	IC886S-100UG
Alexa Fluor Plus 405	FAB886AFP405-100UG
Alexa Fluor Plus 488	FAB886AFP488-100UG
Alexa Fluor Plus 555	FAB886AFP555-100UG
Alexa Fluor Plus 594	FAB886AFP594-100UG
Alexa Fluor Plus 647	FAB886AFP647-100UG
Alexa Fluor Plus 680	FAB886AFP680-100UG
Allophycocyanin	FAB886A
Biotin	FAB886B
CoraFluor 1	FAB886CL1
DyLight 350	FAB886D
DyLight 405	FAB886E
DyLight 488	FAB886K
DyLight 550	FAB886L
DyLight 594	FAB886M
DyLight 650	FAB886W
DyLight 680	FAB886Y
DyLight 755	FAB886Z
HRP	FAB886H
Janelia Fluor 525	FAB886JF525
Janelia Fluor 549	FAB886I
Janelia Fluor 646	FAB886J
Janelia Fluor 669	FAB886JF669
PerCP	FAB886C
Phycoerythrin	IC6472P
mFluor Violet 450 SE	FAB886MFV450
mFluor Violet 500 SE	FAB886MFV500
mFluor Violet 610 SE	FAB886MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	IC6472P
Carrier Free	MAB886-SP
Carrier Free	IC886V-100UG
Carrier Free	IC886G-100UG
Carrier Free	IC886U-100UG
Carrier Free	IC886T-100UG
Carrier Free	IC886S-100UG
Carrier Free	IC886R-100UG
Carrier Free	IC886N-100UG

compare

(select up to 3 products from this page to compare)

DYC647-2

Human Total Survivin DuoSet IC ELISA, 2 Plate

(12 Publications)

1 Kit (for 2 Plates)

DYC647-2

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

Conjugate	Catalog #	Availability	Size	Price
Biotin	DYC647E
Biotin	DYC647-5

compare

(select up to 3 products from this page to compare)

DSV00

Human Survivin Quantikine ELISA Kit

(10 Publications)

1 Kit

DSV00

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Antibody Validation

Reviews

Host

Available Conjugates

Format

Modification

Clonality

Clone

Images Type

Isotype

Preservative

Protein Or Peptide

Research Areas

Has Sample Size

Promotional Item

Species Glossary

Survivin Antibody - BSA Free

Survivin Antibody [Unconjugated]

Survivin Antibody (60.11) - BSA Free

Survivin Antibody (8E2) - BSA Free

Survivin [p Thr34] Antibody - BSA Free

Survivin Antibody (32.1) - BSA Free

Survivin Antibody - BSA Free

Survivin [p Ser20] Antibody - BSA Free

Survivin Antibody Pack

Survivin Antibody (91630) [Unconjugated]

Human Total Survivin DuoSet IC ELISA, 2 Plate

Human Survivin Quantikine ELISA Kit